Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
pharminent
April 1, 2026 (Last updated: April 2, 2026)
BioPharma Dive
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
